Table 2.
Descriptive statistics of body composition variables and health-related quality of life (HRQoL) outcomes of included colorectal cancer survivors by gender and tumor stage
| Gender | Tumor stagea | Total group (n = 104) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Men (n = 62) | Women (n = 42) | Stage I (n = 27) | Stage II (n = 33) | Stage III (n = 38) | ||||||||
| Mean | (SD) | Mean | (SD) | Mean | (SD) | Mean | (SD) | Mean | (SD) | Mean | (SD) | |
| Body composition variablesb | ||||||||||||
| Visceral adipose tissue at diagnosis (cm2) | 160.6 | (100.6) | 100.0 | (67.7) | 143.4 | (90.4) | 134.1 | (91.4) | 124.8 | (92.7) | 136.1 | (93.4) |
| Intermuscular adipose tissue at diagnosis (cm2) | 13.4 | (9.2) | 15.0 | (8.1) | 13.4 | (7.3) | 15.0 | (8.5) | 13.2 | (9.2) | 14.0 | (8.8) |
| Mean muscle attenuation at diagnosis (HU) | 37.8 | (8.4) | 36.2 | (9.2) | 36.2 | (8.0) | 36.0 | (9.7) | 38.8 | (8.2) | 37.1 | (8.7) |
| Skeletal muscle index at diagnosis (cm2/m2) | 51.3 | (5.8) | 42.6 | (5.7) | 47.6 | (6.7) | 47.4 | (7.2) | 48.2 | (8.0) | 47.8 | (7.2) |
| Self-reported BMI at diagnosis (kg/m2) | 25.6 | (3.0) | 25.8 | (4.1) | 26.0 | (4.4) | 25.5 | (3.3) | 25.6 | (3.1) | 25.7 | (3.5) |
| Measured BMI at HRQoL assessment (kg/m2) | 27.2 | (3.3) | 28.4 | (5.5) | 28.5 | (5.2) | 27.7 | (4.6) | 27.2 | (3.5) | 27.7 | (4.3) |
| Maximum handgrip strength at HRQoL assessment (kg) | 44.2 | (9.1) | 26.8 | (5.7) | 33.9 | (10.3) | 37.0 | (12.5) | 37.6 | (11.0) | 37.2 | (11.6) |
| Health-related quality of life outcomes (scale)c | ||||||||||||
| Global quality of life (0–100) | 79.0 | (16.2) | 77.2 | (17.7) | 74.1 | (15.0) | 79.8 | (15.7) | 80.7 | (18.5) | 78.3 | (16.7) |
| Range (min–max) | 25.0–100.0 | 41.7–100.0 | 50.0–100.0 | 33.3–100.0 | 25.0–100.0 | 25.0–100.0 | ||||||
| Physical functioning (0–100) | 84.1 | (19.1) | 77.6 | (21.0) | 80.7 | (18.6) | 79.2 | (19.9) | 82.5 | (21.8) | 81.5 | (20.0) |
| Range (min–max) | 33.3–100.0 | 20.0–100.0 | 46.7–100.0 | 33.3–100.0 | 20.0–100.0 | 20.0–100.0 | ||||||
| Role functioning (0–100) | 87.1 | (23.7) | 79.8 | (27.2) | 84.0 | (21.9) | 83.8 | (25.2) | 82.5 | (29.2) | 84.1 | (25.3) |
| Range (min–max) | 0.0–100.0 | 0.0–100.0 | 33.3–100.0 | 0.0–100.0 | 0.0–100.0 | 0.0–100.0 | ||||||
| Social functioning (0–100) | 89.8 | (18.4) | 91.7 | (13.4) | 90.7 | (13.3) | 88.4 | (19.3) | 91.2 | (17.2) | 90.5 | (16.5) |
| Range (min–max) | 16.7–100.0 | 66.7–100.0 | 66.7–100.0 | 16.7–100.0 | 33.3–100.0 | 16.7–100.0 | ||||||
| Disability (0–100) | 11.6 | (14.7) | 13.4 | (16.6) | 13.1 | (11.9) | 14.8 | (18.2) | 9.3 | (15.5) | 12.3 | (15.4) |
| Range (min–max) | 0.0–61.1 | 0.0–63.9 | 0.0–38.9 | 0.0–63.9 | 0.0–61.1 | 0.0–63.9 | ||||||
| Fatigue (20–140) | 57.2 | (26.6) | 51.3 | (26.7) | 60.1 | (23.8) | 54.9 | (29.7) | 50.9 | (26.7) | 54.9 | (26.6) |
| Range (min–max) | 20.0–134.0 | 20.0–113.0 | 30.4–113.0 | 20.0–134.0 | 20.0–111.0 | 20.0–134.0 | ||||||
| Distress (0–21) | 8.4 | (6.1) | 7.6 | (6.2) | 8.6 | (4.5) | 8.3 | (7.0) | 7.1 | (6.4) | 8.1 | (6.1) |
| Range (min–max) | 0.0–23.0 | 0.0–24.0 | 1.0–19.0 | 0.0–24.0 | 0.0–23.0 | 0.0–24.0 | ||||||
BMI body mass index, HU Hounsfield units
aData missing for 6 men
bData missing for 3 participants (1 man with stage II, 1 man with tumor stage missing, and 1 woman with stage I) for skeletal muscle index, mean muscle attenuation, and intermuscular adipose tissue; and 20 participants (1 man with tumor stage missing, 2 men with stage I, 2 men with stage II, 5 men with stage III, 3 women with stage I, 6 women with stage II, and 1 woman with stage III) for self-reported BMI at diagnosis
cHigher scores indicate higher global quality of life, physical, role and social functioning, disability, fatigue, and distress. Data missing for 3 participants (1 man with stage II, 1 woman with stage I, and 1 woman with stage III) for disability, 2 women with stage II for fatigue, and 1 man with stage II for distress